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ABSTRACT  
Aims This paper presents the potential of environmentally-sourced bacteriophages to affect the 
growth of clinical isolates of Pseudomonas aeruginosa biofilms, and assesses the respective plaque 
morphotypes presented by each bacteriophage, in vitro.  
Methods and Results Bacterial host strains were typed for their ability to produce the quorum 
sensing-controlled virulence factor pyocyanin, and then tested for bacteriophage susceptibility using 
the spot test method. The bacteriophages were co-administered with ciprofloxacin in order to 
determine whether the bacteriophages would demonstrate synergistic or antagonistic behaviour to 
the antibiotic in vitro. Results suggest a potential relationship between the bacteriophage plaque size 
and biofilm inhibition, where those producing smaller plaques appear to be more effective at reducing 
bacterial biofilm formation.  
Conclusions This phenomenon may be explained by a high adsorption rate leading to the rapid 
formation of smaller plaques, and greater biofilm reduction associated with the loss of viable bacterial 
cells before the cells can adhere to the surface and form a biofilm.  Results from the coadministration 
of bacteriophage & ciprofloxacin suggest that the two work synergistically to affect P. aeruginosa 
biofilms.  
Significance and Impact of Study The data indicate enhanced efficacy of ciprofloxacin by ≥50%. This 
could offer an alternative strategy for targeting antibiotic-resistant infections.  
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1 INTRODUCTION  
Pseudomonas aeruginosa is a Gram-negative bacterium, commonly isolated from soil and 
environmental waters. However, it is most often noted for its multi-drug resistance (MDR) to a high 
number of antibiotics commonly prescribed to treat infectious disease in humans (Lambert et al., 
2002; Hirsch & Tam, 2010). The bacterium is frequently isolated from incidents of wound and burn 
infection, as well as cystic fibrosis, and is noted as a leading cause of morbidity and mortality by 
healthcare providers (Kosorok et al., 2001). The persistence of P. aeruginosa in up to 80% of all 
infections is attributed to its ability to form complex biofilms. In one study, Milivojevic et al. (2018) 
showed that the infection ability of forty P. aeruginosa can be predicted based on different virulence 
factors, where a positive correlation between cytotoxicity (an indicator of infection) and biofilm 
formation was found. Bacteria in a biofilm display many different features from their planktonic 
counterparts. These structured and aggregated bacterial communities are known to be notorious for 
their resistance to a variety of antibiotics and the action of host defences (Singh et al., 2017; 
Skariyachan et al., 2018). Thus, a biofilm provides P. aeruginosa a protective mode of growth, where 
individual bacteria can reproduce whilst circumventing external stresses.   
Ciprofloxacin is a fourth-generation quinolone antibiotic, routinely prescribed to treat P. aeruginosa 
infection. The rate of ciprofloxacin resistance by Pseudomonas sp. associated with bacteraemia was 
reported to be static at 11% between 2007 to 2011 in the UK (Anon., 2012). In 2017, the English 
Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) reported that the rate 
of Pseudomonas sp. resistant to ciprofloxacin varied across to the UK between 9.4 to 10.9% of isolates 
(Anon., 2017). Evidence suggests that a delay in prescribing antibiotics to treat P. aeruginosa 
infections is a significant factor leading to increased morbidity of patients, further leading to increased 
mortality (Kang, et al., 2003; Nathwani et al., 2014). Research by Zelenitsky et al. (2005) recommended 
the use of 400 mg i.v. q8h to improve pharmacodynamic target attainment and to effectively treat P. 
aeruginosa infections. Such a treatment regime might prove to be effective to prevent long-term 
morbidity. However, it has been reported that the rate of consumption of antibiotics, including 
ciprofloxacin, is linked to the development of resistance in vitro (Miliani et al., 2011). Indeed, 
Zelenitsky et al. (2005) also suggested that breakpoints should be lowered from 1 to 0.5 mg/mL, and 
then prescription of a maximal dosage might be the most appropriate course of antibiotic treatment 
for such infections. This approach, although appropriate for individual cases of treatment, might lead 
to complications and the spread of antibiotic resistance between bacterial species. For these reasons, 
alternatives to antibiotic prescription must be evaluated alongside potential alternative therapies.   
There are many published reports of alternative therapies being trialled as antibacterial and 
antibiofilm agents, such as microbial exoproducts, plant products, and bacteriophage preparations. 
For example, Papa et al. (2015) reported the antibiofilm but non-biocidal effects of supernatants from 
Arctic and Antarctic bacteria against Staphylococcus aureus, Staphylococcus epidermidis and P. 
aeruginosa. Artini et al. (2018) reported that essential oil extracts from Mediterranean plants were 
able to destabilise P. aeruginosa biofilms without affecting bacterial viability.   
Bacteriophages are obligate intracellular parasites of bacteria. They are specific to only one species, 
sometimes even to one strain of a single bacterial species (Hanlon 2007). For these reasons, 
bacteriophages have been promoted as an alternative therapeutic agent for bacterial infections. For 
P. aeruginosa, research has demonstrated that administration of a single bacteriophage to bacterial 
biofilm cultures achieved a 3-log10 reduction in cell number (Pires et al., 2011). Other than their 
bactericidal properties, bacteriophages have several attractive properties such as low production 
costs, low inherent toxicity and minimal disruption of normal flora (Gorski et al., 2018; Gosh et al., 
2019). Although their application in Eastern Europe is well documented (Merabishvili et al., 2009), the 
western world remains sceptical about the efficacy and safety of phage therapy.   
This paper reports the efficacy of environmentally-sourced bacteriophages against clinical strains of 
P. aeruginosa. Bacteriophages from three different environmental surface waters, were used in this 
study, and characterised according to the morphological characteristics of the plaques developed 
through plating. The potential efficacy of the bacteriophages against bacterial biofilms was evaluated 
in a microtitre plate in single application, or in combination with ciprofloxacin, in order to determine 
whether co-administration of the bacteriophage and antibiotic enhanced the disruption of P. 
aeruginosa biofilms, in vitro.  
2 MATERIALS AND METHODS  
The following materials and reagents were used: L.B. Agar (Liofilchemsrl ReF 610245), L.B. Medium  
(Liofilchemsrl ReF 610084) were used for bacterial growth, glucose (Sigma-Aldrich), casamino acids 
(Sigma-Aldrich), ethanol (Sigma-Aldrich), crystal violet (BioMerieux®SA), acrodisc syringe filters with 
supor membrane, 32 mm, 0.45 μm (Pall corporation), ciprofloxacin (Laboratorio Farmaceutico C.T). 
Plastic and disposable lab consumables were purchased from (VWR), and the centrifuge used in this 
work was manufactured by IEC MultiRF (ThermoIEC).  
2.1 Characterisation of bacteriophages according to their lytic activity against host bacteria  
Eight clinical strains of P. aeruginosa, provided by the culture collection at The Eliava Institute, 
Republic of Georgia, were used in this study (Table 1). These isolates were screened against a total of 
40 bacteriophages isolated from the Mtkvari (Kura) River, Lisi Lake and Turtle Lake in Tbilisi (Republic 
of Georgia), using the spot test technique (Merabishvili et al., 2009). Briefly, overnight cultures of P. 
aeruginosa were diluted to a suspension containing 108 CFU ml-1. An aliquot of 200µL was added to 
4mL molten 0.7% (w/v) LB agar, and deposited on the surface of 1.5% (w/v) LB agar plates. Plates were 
air-dried, spotted with 5µL (107 PFU ml-1) of each of the bacteriophage suspensions, and incubated at 
37°C for 18h.  Lytic zones were evaluated according to the following  
criteria.  
(i) Confluent lysis (Cl), a zone of clearing.    
(ii) Opaque lysis (Ol), a film of fine growth on area of dropped phage.   
(iii) Semi-confluent lysis (Scl), high amount of growth on area of dropped phage.  
(iv) Several plaques (Sp), multiple zones of clearing.   
(v) Resistant (R), no zone of clearing.      
2.2 Assessment of plaque morphotype  
Using the overlay agar method (Merabishvili et al., 2009), suspensions of bacteriophages that 
demonstrated Cl or Ol in the screening assay were used to determine the titre, and assess the 
morphology and clarity of the plaques produced. Briefly, serial dilutions of each bacteriophage were 
prepared in LB broth. An aliquot of 100µl of each dilution was mixed with 4ml molten 0.7% (w/v) LB 
agar, containing a suspension of P. aeruginosa PS 573 at 108 CFU ml-1. This mixture was deposited on 
the surface of 1.5% (w/v) LB agar plates, and plates were incubated at 37°C for 24h. Plates with 1 to 
200 distinguishable homogenous plaques were enumerated, and the number of plaque forming units 
(PFU ml-1) was determined using equation (a).  
(a) PFU ml-1 = number of plaques  x  (1 / volume of phage plated [ml])  x  dilution factor     
To ensure the purity of the selected bacteriophage suspensions (i.e. that they did not contain a mixture 
of bacteriophage clones), all plaques with different morphology were removed with a sterile pipette 
tip, and placed in 1ml LB broth. These were incubated at 37°C for 1h to allow lysis of adherent bacterial 
cells. The tubes were then placed at 4°C for 1h, before the lysate suspension was filtered using a 
0.45µm membrane filter. Serial dilutions of each suspension were prepared in LB broth, and each 
dilution was titrated using the overlay agar method. Plates showing 5-20 plaques were analysed in 
detail. This complete cycle was repeated until homogenous plaques were obtained.  
Pure suspensions, containing one clear plaque morphotype, were obtained after several cycles at a 
PFU ml-1 of 107. Following several cycles of purification, pure stock suspensions of selected 
PTbacteriophages were prepared using the double-agar overlay method previously described. Briefly,  
1ml LB was added to the surface of plates with homogenous plaques, and incubated at 4°C for 1h. The 
top (soft) agar layer was then removed using a sterile L-shaped rod, and transferred to a 50ml 
centrifuge tube. The mixture was centrifuged at 6000g for 20 min, at 4°C. The supernatant was 
aspirated using a sterile 10ml syringe with a 30G needle, and filtered through a 0.45µm membrane 
filter. The titre of the stock suspension was determined as described using the agar overlay method.  
Stock suspensions of purified PT-bacteriophages were obtained at 109-1010 PFU mL-1.   
2.3 Pyocyanin assessment  
Overnight cultures of P. aeruginosa strains (detailed in Table 1) were grown in nutrient broth at 37°C 
with agitation of 120rpm for 24h. The supernatants were recovered by centrifugation at 4500 g for 20 
min at 4°C, and filtered using a 0.2µm syringe filter. Pyocyanin production was visually assessed and 
scored: 0, no pigmentation, 1+ weak pigmentation, 2+ moderate pigmentation, and 3+ strong 
pigmentation (El-Shouny et al., 2011).  
2.4 Biofilm studies  
The anti-biofilm potential of purified bacteriophages, ΦPT-18[b], ΦPT-20[a], ΦPT-1S[a], ΦPT-5[a] 
and ΦPT-2[b] (Glonti, 2004; Glonti et al., 2010; Ceyssens et al., 2011), was assessed on P. aeruginosa  
PS 573 alone, and in combination with ciprofloxacin, using the crystal violet biofilm assay (O'Toole, 
2011). This static batch-growth biofilm assay was therefore used for examining the formation of 
biofilms in the early stages of biofilm maturation, termed microcolony development (≤24h). This 
method is preferable for this work, as opposed to continuous-flow methods, as it can be used to 
monitor microbial attachment to an abiotic surface and detect the transition from planktonic to 
biofilm mode of growth (O'Toole & Kolter, 1998; Caiazza & O'Toole, 2004). In brief, the assay involved 
the growth of cells in a 96-well polystyrene microtiter plate or individual polystyrene plates at pre-
determined nutrient conditions. After incubation, any non-adherent cells were removed by washing 
and adherent cells were stained with a dye to allow visualisation of the biofilm. The dye was then 
solubilised to provide semi-quantitative data. Biofilm media was prepared using 1x LB broth, 
supplemented with 0.4% (w/v) glucose and 0.5% (w/v) casamino acids. These nutrient conditions were 
designed through in-house optimisation to provide maximal biofilm growth and result in the 
formation of a robust biofilm, which can be used to test the effectiveness of potential biofilm  
inhibitors.   
Fresh cultures of P. aeruginosa PS 573 were prepared in 5mL LB broth and incubated at 200rpm for  
3h. Cultures were then diluted 1:10 in biofilm growth media to achieve a final concentration of 1 x 10 
CFU ml-1. Purified bacteriophages were prepared at low and high titres in biofilm media to achieve a 
final titre of 1 x 103 and 1 x 108 PFU ml-1, respectively. For bacteriophage and antibiotic combination 
studies, purified bacteriophages were prepared in biofilm media at low titres (103 PFU ml-1) and 
supplemented with ciprofloxacin at the minimal inhibitory concentration of 0.5µg ml-1. All 
components were added to a sterile tube to a total volume of 5mL, mixed for 30s, and poured into  
50mm polystyrene UV-sterilised plates. These plates were sealed with parafilm and incubated at 37°C 
for 22 ± 2h, without agitation. Growth control wells containing untreated P. aeruginosa PS 573 
cultures and sterile biofilm media were also included.   
After incubation, the contents of each plate were decanted, and plates were washed with distilled 
water to remove any non-adherent cells. Plates were air-dried for 5-10 minutes, and adherent cells 
were stained with 6mL 10% (v/v) crystal violet for 15 minutes. The dye was removed, and each plate 
was washed 6 times with distilled water to remove excess stain. To quantify the biofilm, stain was 
solubilised in 6mL 95% (v/v) ethanol for 25 minutes. Two-mL aliquots were transferred into sterile 
cuvettes, and absorbance was measured at 550nm, using 95% (v/v) ethanol as the blank. Preliminary 
studies confirmed that PS 537 produces a biofilm biomass similar to that of PAO1, a biofilm-forming 
lab strain (data not shown). Absorbance values lower than the untreated control were indicative of 
less crystal violet staining and therefore low biofilm growth.   
2.5 Data analysis   
All experiments were performed at least three independent times unless stated otherwise (n). Data 
are expressed as the mean of independent experiments ± the standard deviation (SD). Data obtained 
from each experiment were processed using Microsoft Office Excel 2011 (USA) and/ or GraphPad 
Prism 6 (GraphPad Software Inc., USA). Statistical analysis was performed using the statistical software 
package of GraphPad Prism 6. Significant differences between mean were assessed using one-way 
analysis of variance (ANOVA) and Tukey’s Post-Hoc test, with a 95% confidence interval. Two-sided 
Student’s t-test was used where appropriate. P-values of < 0.05 were considered  
statistically significant.  
3 RESULTS  
3.1 Lytic activity of environmental bacteriophages against host P. aeruginosa   
The screening of the bacteriophages against clinical strains of P. aeruginosa identified varying degrees 
of lytic activity, which was assessed by the relative clarity of the plaques (Table 2, and Figure 1). The 
bacteriophages showed 10-98% lytic activity against the clinical isolates, however, it must be noted 
that this was only observed against pyocyanin-deficient strains.     
Results indicate that bacteriophage PT-1(B/M/S/X), belonging to the Myoviridae family of 
bacteriophages, was capable of forming clear plaques on all pyocyanin-deficient P. aeruginosa strains 
(63% of all isolates); specifically, PS 112, PS 114, PS 317, M 317 and PS 573, and displayed a broader 
host range against the P. aeruginosa strains than the remaining bacteriophages. None of the 
bacteriophages were able to produce clear plaques or demonstrate any signs of lytic activity against 
pyocyanin-proficient strains (PS 118, PS 119 and PS 1123). Pyocyanin production is a terminal signal 
of quorum sensing, and a potent virulence factor of P. aeruginosa (Dietrich et al., 2006; Milivojevic et 
al., 2018), and the results may therefore suggest that a reduction in pathogenicity enhances the lytic 
activity of the aforementioned bacteriophages. This observation is, however, limited to three bacterial 
strains, and the hypothesis needs to be further assessed using several wild-type and quorum sensing-
deficient strains and/or by combining these bacteriophages with a compound that reduces 
pathogenicity such as a quorum sensing inhibitor. The bacteriophages produced the clearest plaques 
on PS 573 (98% lytic activity, Figure 2), and this strain was therefore selected as host for subsequent 
purification and propagation of the bacteriophages.   
3.2 Assessment of plaque morphotype  
The bacteriophages were selected based upon their plaque morphotype, which was determined by 
using P. aeruginosa PS 573 as the host strain. Results are shown in Figure 4 and Table 3, and the data 
are defined as follows.      
(i) ФPT-18[b]: very small, clear plaques with a diameter of ≤ 0.5mm.  
(ii) ФPT-20[a]: very small, clear plaques with a diameter of ≤ 0.5mm.   
(iii) ФPT-1S[a]: small, clear plaques with a diameter of 1-2mm.   
(iv) ФPT-5[a]: small, clear plaques with a diameter of 2mm.  
(v) ФPT-2[b]: large, clear plaques with a diameter of ≥ 3mm.   
3.3 Biofilm studies  
The crystal violet biofilm assay stains both live and dead bacterial cells, as well as extracellular matrix 
polymers. Results indicate that P. aeruginosa PS 573 is a strong biofilm-producing strain. The biofilm 
formed by this strain was moderately resistant to disruption during the mechanical washing steps. 
The addition of bacteriophages, ΦPT-18[b], ΦPT-20[a], ΦPT-1S[a], ΦPT-5[a] and ΦPT-2[b] in to the 
test media indicated that all of the bacteriophages tested were all able to reduce the rate at which 
planktonic cells of P. aeruginosa formed a biofilm (Figure 4[a-c] and 5[a-c]). A higher titre (108  
PFU/mL) was more effective at preventing biofilm formation than a lower titre of 103 PFU/mL (Figure 
3[a-c] and 4[a-c]), respectively. Of the five bacteriophages tested, ΦPT-18[b] and ΦPT-20[a] (which 
form plaques with a diameter of ≤ 0.5mm) appeared to be most effective and reduced biofilm biomass 
by approximately 87.6 and 84.6% when applied at 108 PFU/mL, respectively (Figure 5[a-c]).   
3.4 Co-administration of ciprofloxacin and PT bacteriophages to biofilms   
Exposure to bacteriophages ΦPT-18[b], ΦPT-20[a], ΦPT-1S[a], ΦPT-5[a] and ΦPT-2[b], rendered the 
biofilm-associated bacterial cells more susceptible to ciprofloxacin (Figure 6[a-c]). Administration of 
ciprofloxacin alone was able to reduce biofilm biomass production by approximately 68.5%, when 
compared to the untreated P. aeruginosa PS 573 control. However, the combination of phages with 
ciprofloxacin appeared to provide a synergistic effect against the establishment of a biofilm, increasing 
the inhibitory effects to 61.8%, when compared to the growth control (P < 0.05, ANOVA). Additionally, 
phage-antibiotic-treated biofilms retained a limited amount of stain, which is likely to be due to the 
presence of a low number of cells. Therefore, these biofilms resembled negative control plates, 
suggesting that the bacteriophages appeared to enhance the efficacy of ciprofloxacin,  
in vitro.    
4 DISCUSSION  
From the total number of forty bacteriophages derived from environmental surface waters in this 
study, the majority were only effective against pyocyanin-deficient strains of P. aeruginosa. Five of 
these bacteriophages produced unique plaque morphologies of ≤ 0.5 to ≥ 3mm in diameter, which is 
are notably smaller than the plaques produced by the other isolated bacteriophages. Analysis of the 
data suggests a potential relationship exists between the plaque size that each bacteriophage 
produced using the agar overlay method and biofilm inhibition, in vitro. Different bacteriophages for 
the same host bacterial species have been reported to produce different plaque sizes on agar plates, 
in vitro (Bremner et al., 2016). The literature further indicates that the adsorption rate contributes to 
the phenotype of plaques, where high-adsorption phages tend to produce smaller plaques (Gallet et 
al., 2011). It must be noted that high rates of adsorption may not necessarily lead to all bacteriophages 
completing their infection cycle. Mitarai et al. (2016) reported that plaque morphology can be affected 
by the nutritional state of the host bacterial cell, and the number of bacteriophages that can infect 
them. This is important, as the nutritional and metabolic state of bacterial cells within biofilms will be 
different to those in planktonic culture, as well as differences existing between early-stage and mature 
biofilm-dwelling cells. A high adsorption rate may explain the greater reduction in biofilm formation 
observed in this study. If bacteriophages ΦPT-18[b] and ΦPT-20[a] are indeed able to adhere to cells 
more efficiently, then this may cause lysis before P. aeruginosa is able to attach to the abiotic surface. 
Extracellular polymers that constitute the biofilm are likely to exert a protective effect for bacterial 
cells (Ghafoor et al., 2011; Colvin et al., 2012; Irie et al., 2012; Zhao et al., 2013). Therefore, the 
potential for bacteriophages to reduce bacterial cell counts would be assumed to be maximal against 
planktonic cells, followed by early-stage, and then mature biofilms. The anti-biofilm potential of 
purified PT-bacteriophage preparations suggested that when added in combination with 
ciprofloxacin, ΦPT-18[b], ΦPT-20[a], ΦPT-1S[a], ΦPT-5[a] and ΦPT2[b] were found to act 
synergistically and to enhance the reduction of bacterial load by ≥50%. The findings presented in this 
paper suggest the potential synergy of bacteriophage-antibiotic preparations to effectively reduce 
biofilm formation by P. aeruginosa. This could offer an alternative strategy for targeting antibiotic-
resistant infections.  
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Table 1. Strains of P. aeruginosa used in this study.  
Strain number  Description *  
PS 112  rhl and/or PQS-deficient; PYO negative (0+)  
PS 114  rhl and/or PQS-deficient; PYO negative (0+)  
PS 118  rhl and/or PQS-proficient; PYO positive (2+)  
PS 119  rhl and/or PQS-proficient; PYO positive (3+)  
PS 317  rhl and/or PQS-deficient; PYO negative (0+)  
M 317  rhl and/or PQS-deficient; PYO negative (0+)  
PS 573  rhl and/or PQS-deficient; PYO negative (0+)  
PS 1123  rhl and/or PQS-proficient; PYO positive (3+)  
* Bacterial strains were grouped based on their ability to produce the quorum sensing-controlled 
virulence factor pyocyanin (PYO): (i) rhl and/or PQS-deficient strains that produced no detectable 
pyocyanin levels, and (ii) rhl and/or PQS-proficient strains that produced detectable pyocyanin levels. 
Pyocyanin levels were qualitatively determined; 0+ no pigmentation, 1+ weak pigmentation,  
2+ moderate pigmentation, and 3+ strong pigmentation.   
Table 2. Susceptibility of P. aeruginosa strains to a series of PT-bacteriophages *.   
 PS 112  PS 114  PS 118  PS 119  PS 317  M 317  PS 573  PS 1123  
PT-1  Cl  Cl  R  R  Cl  Cl  Cl  R  
PT-2  R  R  R  R  R  R  Ol  R  
PT-3  R  R  R  R  R  R  Ol  R  
PT-4  R  R  R  R  R  R  Ol  R  
PT-5  R  R  R  R  R  R  Ol  R  
PT-6    R  R  Sp  R  R  R  Ol  R  
PT-7  Scl  R  R  R  Cl  Cl  Ol  R  
PT-7x  Scl  R  R  R  Cl  Cl  Ol  R  
PT-8  R  R  R  R  Sp  Sp  Sp  R  
PT-10  R  R  Sp  R  R  R  Ol  R  
PT-12  R  Scl  R  R  Sp  R  Scl  R  
PT-14  R  R  R  R  Sp  R  Cl  R  
PT-14x  R  R  R  R  Sp  R  Cl  R  
PT-15  R  R  R  R  R  R  R  R  
  
  
Ф  
Pseudomonas aeruginosa  test strains  
PT - 2 .K 8  R  R  R  R  R  R  Ol  R  
PT - 4 .K 2  R  R  R  R  R  R  Ol  R  
PT-17  R  R  R  R  Sp  Sp  Ol  R  
PT-18  R  R  R  R  R  R  Cl  R  
PT-19  R  R  R  R  R  R  Cl  R  
PT-20  R  R  R  R  R  R  Cl  R  
PT-35  R  R  R  R  R  Sp  Scl  R  
PT-40  R  R  R  R  R  Sp  Cl  R  
PT-1B  Cl  Cl  R  R  Cl  Cl  Cl  R  
PT-1M  Ol  Cl  R  R  Cl  Cl  Cl  R  
PT-1S  Cl  Cl  R  R  Cl  Cl  Cl  R  
PT-1X  Cl  Cl  R  R  Cl  Cl  Cl  R  
PT-2.K2  R  R  R  R  R  R  Ol  R  
PT-2.K4  R  R  Sp  R  R  Sp  Ol  R  
PT-2.K5  R  R  R  R  R  R  Ol  R  
PT-2.K7  R  R  R  R  R  R  Ol  R  
 
 
PT-4.K3  R  R  R  R  R  R  Ol  R  
 
 
 
   
    
    
    
  
   
   
